Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

May 13, 2022

SELL
$223.2 - $571.2 $8.76 Million - $22.4 Million
-39,248 Closed
0 $0
Q4 2021

Feb 11, 2022

BUY
$374.4 - $1500.0 $14.7 Million - $58.9 Million
39,248 New
39,248 $68,000

Others Institutions Holding DRMA

# of Institutions
1
Shares Held
0
Call Options Held
0
Put Options Held
0

About Dermata Therapeutics, Inc.


  • Ticker DRMA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 10,102,200
  • Market Cap $13.5M
  • Description
  • Dermata Therapeutics, Inc., a clinical-stage biotechnology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe ...
More about DRMA
Track Jim Simons's Portfolio

Track Jim Simons Portfolio

Follow Jim Simons (Renaissance Technologies LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.